Moderate
Amiodarone × carvedilol
Class III antiarrhythmics (Vaughan Williams)×Alpha and beta blocker (non-selective β + α1)
Mechanism
Additive bradycardia and QT effect from amiodarone, on top of carvedilol's negative chronotropy. Often used in heart failure with reduced ejection fraction and atrial fibrillation — an acceptable combination.
Symptoms
Bradycardia, dizziness, fatigue, near-syncope. QT prolongation on ECG. Dizziness, syncope, palpitations. Rarely: polymorphic ventricular tachycardia (torsades de pointes). Risk is higher with hypokalaemia, hypomagnesaemia, bradycardia, and ischaemic heart disease.
Management
Start carvedilol at minimum dose (3.125 mg twice daily) with up-titration every 2 weeks. Check ECG and heart rate at 1 and 4 weeks. If heart rate falls below 50 bpm or 2nd/3rd-degree AV block develops, adjust both. Keep potassium and magnesium in the upper half of normal range.
Sources
- ESC: 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure (2021)– Eur Heart J 2021;42(36):3599–3726